How to assess response to immune therapy
DOI:
https://doi.org/10.19156/cbn.2016.0029Keywords:
microbiota, PD-L1, pseudo-progression, RECIST, local and peripheral immune responseAbstract
Immunotherapy is already a mainstay in treating melanoma, lung cancer and renal cancer and shows compelling promise in many different tumors. However, responses to immunotherapy may be present despite apparent initial progression of the tumor. This underlines the importance of defining accurate tumor assessments and response criteria for immunotherapy. The RECIST criteria have therefore been modified to adhere to requirements of immunotherapy. In line with that, this review will focus on the current imaging tools, the statistical evaluations in clinical trials and the biological analysis of the tumor microenvironment that will in the future effectively guide treatment decisions in everyday clinical practice.Downloads
Published
2016-12-15
How to Cite
1.
Michels J, Lanoy E, Caramella C, Marth C. How to assess response to immune therapy: . CBN [Internet]. 2016 Dec. 15 [cited 2024 Nov. 24];4(3):47-51. Available from: https://journals.aboutscience.eu/index.php/cancerbreakingnews/article/view/225
Issue
Section
Methodological corner
License
Articles published in Cancer Breaking News are distributed under the CC Attribution-NonCommercial-NoDerivatives 4.0 license, which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.